ArticleHeliyon2022
Impact of elevated first and second trimester white blood cells on prevalence of late-onset preeclampsia.
Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-based prediction of preeclampsia using first-trimester inflammatory markers and red blood cell indices.BMC pregnancy and childbirth · 2025Article
- Prognostic value of systemic immune-inflammation index in the diagnosis of preeclampsia.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Increased white blood cell count (WBC) is known to be associated with preeclampsia (PE). This study aimed to determine whether WBC count >10×10 Methods: This prospective study was conducted in 600 pregnant women from Shanghai Pudong Hospital in China from July 2019 to August 2020. They were classified into four groups: Group 1: WBC count ≤10×10 Results: 34 women were diagnosed with LOPE at predelivery. The estimated incidence rate of LOPE during pregnancy was 3.6% in Group 1, 5.8% in Group 2, 7.2% in Group 3, and 11% in Group 4 for the respective WBC level of Group 1, 2, 3 and 4. After adjusting for potential influencing factors of PE, the respective relative risks for LOPE was 1.0 (reference), 1.76 (95% CI 0.37, 8.30), 2.23 (0.85, 5.89), and 3.07 (1.34, 7.02) (P for trend = 0.048). Conclusions: Our results demonstrated that WBC count >10×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.